693 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Monday’s Close
AMGN Amgen Inc. $200.81 $129.98B N/A
Article Searches
Stock Market News for September 09, 2015 http://www.zacks.com/stock/news/189402/stock-market-news-for-september-09-2015?cid=CS-ZC-FT-189402 Sep 09, 2015 - Benchmarks ended higher on Tuesday after weak Chinese trade data raised hopes that further stimulus measures will be announced to boost its fragile economy
Novartis (NVS) Launches Zarxio: First Biosimilar in the U.S. http://www.zacks.com/stock/news/188907/novartis-nvs-launches-zarxio-first-biosimilar-in-the-us?cid=CS-ZC-FT-188907 Sep 03, 2015 - Novartis (NVS) launched Zarxio (biosimilar version of Amgen's Neupogen) in the U.S., which became the first FDA-approved biosimilar to be launched in the country.
The Zacks Analyst Blog Highlights: Amgen, ARIAD, Celgene, Amicus and Alnylam http://www.zacks.com/stock/news/188832/the-zacks-analyst-blog-highlights-amgen-ariad-celgene-amicus-and-alnylam?cid=CS-ZC-FT-188832 Sep 03, 2015 - The Zacks Analyst Blog Highlights: Amgen, ARIAD, Celgene, Amicus and Alnylam
Amgen, Novartis Team Up; Bone Drug Positive in Phase III http://www.zacks.com/stock/news/188757/amgen-novartis-team-up-bone-drug-positive-in-phase-iii?cid=CS-ZC-FT-188757 Sep 02, 2015 - Amgen (AMGN) inks deal with Novartis for Alzheimer's disease and migraine; reports positive phase III data on romosozumab.
Regeneron and Sanofi Present Encouraging Praluent Data http://www.zacks.com/stock/news/188756/regeneron-and-sanofi-present-encouraging-praluent-data?cid=CS-ZC-FT-188756 Sep 02, 2015 - Regeneron Pharmaceuticals, Inc. (REGN) and its partner Sanofi (SNY) presented encouraging data from a phase III study on their Praluent, at the ESC Congress 2015.
AstraZeneca Strikes Deal with Valeant for Psoriasis Drug http://www.zacks.com/stock/news/188754/astrazeneca-strikes-deal-with-valeant-for-psoriasis-drug?cid=CS-ZC-FT-188754 Sep 02, 2015 - AstraZeneca (AZN) strikes a collaboration agreement with Valeant for the development and commercialization of brodalumab.
Biotech Stock Roundup: Amgen in the News, ARIAD a Takeover Target? http://www.zacks.com/stock/news/188645/biotech-stock-roundup-amgen-in-the-news-ariad-a-takeover-target?cid=CS-ZC-FT-188645 Sep 02, 2015 - ARIAD's (ARIA) shares shot up on acquisition rumors; Amgen (AMGN) gained FDA approval for its potential blockbuster treatment, Repatha.
Alnylam Presents Positive Data on PCSK9 Synthesis Inhibitor http://www.zacks.com/stock/news/188389/alnylam-presents-positive-data-on-pcsk9-synthesis-inhibitor?cid=CS-ZC-FT-188389 Aug 31, 2015 - Alnylam (ALNY) and The Medicines Company (MDCO) presented initial data from their ongoing phase I study on ALN-PCSsc for the treatment of hypercholesterolemia.
Amgen's PCSK9 Inhibitor, Repatha, Approved in the U.S. http://www.zacks.com/stock/news/188143/amgens-pcsk9-inhibitor-repatha-approved-in-the-us?cid=CS-ZC-FT-188143 Aug 28, 2015 - Will FDA approval of Amgen's (AMGN) Repatha trigger a pricing war for this class of treatment?
The Zacks Analyst Blog Highlights: Vital Therapies, Amgen, BioMarin, Acorda and Macrocure http://www.zacks.com/stock/news/187958/the-zacks-analyst-blog-highlights-vital-therapies-amgen-biomarin-acorda-and-macrocure?cid=CS-ZC-FT-187958 Aug 27, 2015 - The Zacks Analyst Blog Highlights: Vital Therapies, Amgen, BioMarin, Acorda and Macrocure

Pages: 1...64656667686970

<<<Page 69